A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
Phase 1
Active, not recruiting
- Conditions
- Colon CancerResected Stage
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05040568
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Phase 1
Terminated
- Conditions
- Breast Inflammatory CarcinomaRecurrent Breast Inflammatory CarcinomaStage IV Breast Inflammatory Carcinoma
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05041101
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Head and Neck Squamous Cell CarcinomaAdvanced Ovarian Clear Cell AdenocarcinomaChondrosarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05039801
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
Phase 2
Recruiting
- Conditions
- ChordomaMetastatic ChordomaUnresectable Chordoma
- Interventions
- Biological: CetuximabOther: Questionnaire Administration
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05041127
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
Early Phase 1
Recruiting
- Conditions
- Advanced Gastric AdenocarcinomaClinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction AdenocarcinomaPathologic Stage III Gastric Cancer AJCC v8Pathologic Stage IIIA Gastric Cancer AJCC v8Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Gastric Cancer AJCC v8Pathologic Stage IIIC Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05041153
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
Recruiting
- Conditions
- PneumoniaHematopoietic System--CancerPulmonary
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05041140
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Phase 2
Withdrawn
- Conditions
- Liver CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05039736
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Phase 1
Recruiting
- Conditions
- Recurrent GliosarcomaRecurrent Glioblastoma
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05039281
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Refractory Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT05038839
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pilot Study
Not Applicable
Active, not recruiting
- Conditions
- Smoking CessationTobacco
- Interventions
- Device: smartphone applications
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT05038852
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath